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INTRODUCTION
Recent studies have suggested that
only a small subpopulation of cells
within solid tumors are capable of self-
renewal and of generating tumors in
mice that resemble the tumor of origin,
which has led to a new model of tumori-
genesis called the cancer stem cell (CSC)
concept. CSCs give rise to the differenti-
ated progeny that constitute the bulk of
the tumor and thus contributes to the
tumor’s cellular heterogeneity (1–5).
CSCs are thought to be responsible for
metastatic potential and possess innate
resistance mechanisms against chemo-
therapy- and radiation-induced cancer
cell death, while the bulk of a tumor
lacks these capacities (6–9). The resis -
tance mechanisms may cause these cells
to survive and become the source of later
tumor recurrence (10–14), highlighting
the need for therapeutic strategies that
specifically target pathways central to
these CSCs, such as Notch, Hedgehog
and Wnt (15). However, such approaches
are not straightforward, since they may
harm the normal stem cell population
and are challenged by the presence of
plasticity between populations of cancer
cells (16–18).
Advances have been made in identify-
ing and enriching tumor-initiating cells
with CSC features in several cancer
types, including breast, brain and colon,
but additional protein markers specific
for, or associated with, this cell popula-
tion are needed (9,19–21). In breast can-
cer, Al-Hajj et al. (9) demonstrated that
cells derived from breast cancer metas-
tases with a CD44hi/CD24–/lo/lineage–/
epithelial cell adhesion (ESA)+ pheno-
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type were enriched for cells exhibiting
CSC characteristics (9), and recent clini-
cal studies showed that residual breast
tumor cell populations, upon neoadju-
vant chemotherapy, were enriched by
CD44hi/CD24–/lo defined breast CSCs
and that these cells had increased expres-
sion of mesenchymal markers (22). More
recently, a few other markers preferen-
tially expressed on CSC-like cells were
reported, including CXCR1 and alde-
hyde dehydrogenase (ALDH), as as-
sessed by the ALDEFLOUR™ assay
(23–25). CD44hi/CD24–/lo cells are most
common in basal-like subtypes of breast
cancer and are very low in HER2+
 tumors (26).
It has been proposed that CSCs are
linked to the epithelial-to-mesenchymal
transition (EMT), wherein epithelial cells
transform into a more invasive and
motile mesenchymal-like phenotype,
which drives tumor cell dissemination
(27,28). Subsequently, the disseminated
mesenchymal-like tumor cells must un-
dergo the reverse transition, mesenchy-
mal-to-epithelial transition (MET), at the
site of metastases, which recapitulates
the pathology of the corresponding pri-
mary tumors (29,30). Therefore, pheno-
typic plasticity between epithelial-like
and mesenchymal-like cells in the forma-
tion of CSCs has major implications for
therapeutic approaches (31). In this re-
gard, a recent transcriptional analysis of
basal-like breast cancer cell lines identi-
fied two major subclasses (basal A and
basal B clusters), in which basal B ap-
peared mesenchymal-like, whereas basal
A may have either luminal-like or basal-
like morphology (32).
To address these issues in more depth,
we generated a panel of isogenic single-
cell clones with either mesenchymal-like
CD44hi/CD24– or epithelial-like CD44hi/
CD24lo phenotypes from a triple-
 negative (estrogen receptor [ER]–, prog-
esterone receptor [PR]–, HER2–) cell line.
This breast cancer subtype was chosen
because these patients display high lev-
els of CD44hi/CD24–/lo cells and have a
poor prognosis. No targeted therapy is
currently available for this subtype, lim-
iting medical treatment to chemother-
apy. Somewhat surprisingly, our results
showed that the cells that exhibited
CSC-like characteristics, such as
CD44hi/CD24–/lo expression, the forma-
tion of mammospheres, initiation of
 tumors in mice and resistance to chemo-
therapy, displayed epithelial-like mor-
phology and characteristics correspon-
ding to the basal A subtype, indicating
that this CSC-like population should
also be targeted by novel treatments.
Importantly, the tumors established
from the epithelial-like single-cell clone
with CSC-like features contained both
cancer cells with epithelial-like, basal A
characteristics, as well as cancer cells
with mesenchymal-like, basal B charac-
teristics, indicative of EMT in the pro-
cess of tumor formation. Our transcrip-
tomic and proteomic analyses provide 
a list of new  biomarkers of the 
mesenchymal-like CD44hi/CD24– sub-
populations as well as epithelial-like
CD44hi/CD24lo subpopulations. The sig-
nificance of selected biomarkers was
confirmed in other cell lines of the basal
A and basal B phenotypes, respectively.
Finally, a 31-gene breast cancer signa-
ture capable of predicting recurrence of
ER– patients is presented, suggesting
that tumors derived from patients with
poor outcome contained more cells with
CSC-like features. Interestingly, no
prognostic signature for ER+ patients
could be identified, suggesting that
CSC-associated genes differ among sub-
types of breast cancer.
MATERIALS AND METHODS
Cell Lines
HMT3909 and clones thereof originate
from a biopsy of human primary infil-
trating ductal breast carcinoma contain-
ing both medullary and intraductal com-
ponents (33). HMT3909S13 and clones
thereof, including A4 and G4, were de-
rived from HMT3909S8 described by Pe-
tersen et al. (33). HMT3909S13-derived
cell lines were cultured in PureCol-
coated (Advanced BioMatrix Inc., San
Diego, CA, USA) flasks in serum-free
medium (mammary epithelial basal me-
dium [MEBM]; Lonza Group Ltd, Basel,
Switzerland) with supplements
(MEGM™ Mammary Epithelial Cell
Growth Medium): SingleQuots Kit (Clo-
netics™; Lonza), 10 ng/mL fibroblast
growth factor (FGF), 20 ng/mL epider-
mal growth factor (EGF; PeproTech,
Rocky Hill, NJ, USA), 2% B27 (Gibco;
Life Technologies Corporation, Grand Is-
land, NY, USA) and 4 μg/mL heparin
(Sigma-Aldrich, St. Louis, MO, USA).
MDA-MB-231, MDA-MB-468, T47D,
MCF7 and Hs578T cell lines were ob-
tained from ATCC and cultured in 
Dulbecco’s modified Eagle medium, 
10% fetal bovine serum, 1% penicillin/
streptomycin and 1% nonessential amino
acids (Gibco; Life Technologies Corpora-
tion). Cells were harvested with Accutase
(EMD Millipore, Billerica, MA, USA).
HMT3909S13 cells treated with chemo -
therapeutics were cultured as described
above, but 24 h after seeding, these cells
were subjected to paclitaxel, doxorubicin,
methotrexate and salinomycin for 10 d.
The medium and chemo therapeutics
were replaced every third day. A4 and
G4 were transfected with the luciferase
gene Luc2 using Lentifire, a ready-to-use
lentivirus-based delivery system (In Vivo
Imaging Solutions, Fort Collins, CO,
USA). Clones of HMT3909S13 were au-
thenticated by G-band karyotyping (Sup-
plementary Figure S1), and all cell lines
were frequently tested for mycoplasma.
Antibodies
Flow cytometry included the follow-
ing: phycoerythrin (PE)-conjugated 
anti-human CD44 (isotype control PE-
conjugated IgG2b; BD Pharmingen; BD,
Albertslund, Denmark), Alexa Fluor 647–
 conjugated anti-human CD24 (isotype
control Alexa Fluor 647-conjugated
IgG2a; Biolegend, San Diego, CA, USA),
anti-human lipolysis-stimulated lipopro-
tein receptor (LSR) (Abcam, Cambridge,
UK) and anti-human RAB25 (Abnova,
Taipei City, Taiwan). Immunocytochem-
istry (ICC)/immunohistochemistry (IHC)
included the following: anti-human
CK5/6, CK7/8, CK17, CK18, CK19,
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HER2,  vimentin, mucin 1 (MUC1), ESA,
PR (Dako, Glostrup, Denmark), CK14,
EGF receptor (EGFR), ER (Novacastra;
Leica Microsystems GmbH, Wetzlar, Ger-
many), CK6A (Novus Biologicals, Little-
ton, CO, USA), E-cadherin (Abcam), inte-
grin α6, ZEB1, LSR (Atlas Antibodies,
Stockholm, Sweden), S100A14 (Protein
Tech Group, Chicago, IL, USA), CD24
(Neo Markers, Fremont, CA, USA), inte-
grin β1 (Biogenex, Fremont, CA, USA),
fluorescein isothiocyanate (FITC)-
 conjugated goat anti-rabbit IgG (Pierce;
Thermo Fisher Scientific, Rockford, IL,
USA), and FITC- conjugated goat anti-
mouse (Zymed; Life Technologies Corpo-
ration). Western blotting included the
following: ZEB1 (Atlas Antibodies),
S100A14 (Protein Tech Group) and goat
anti-rabbit IgG (Dako).
Flow Cytometry
Cells were resuspended in HEPES
buffer with protease inhibitors (Roche
Diagnostics, Hvidovre, Denmark). For
intracellular staining, cells were fixed in
ethanol, permeabilized in 0.2% saponin
and blocked with 10% normal goat
serum. Samples were incubated with flu-
orochrome-conjugated antibodies fol-
lowed by flow cytometry (FACSCalibur;
BD Biosciences, San Jose, CA, USA) or
 fluorescence-activated cell sorting
(FACSDiva; BD Biosciences). Mean fluo-
rescence intensity is defined as geometric
mean value of the fluorescence.
Mammosphere Assay
Dilution series of cells were seeded on
ultra-low attachment plates in serum-
free medium and incubated for 18 d.
Clones were trypsinized into single-cell
suspensions, diluted and seeded into
new wells for mammosphere formation




Tissue or cells were fixed in formalin
and were paraffin embedded. Antigen re-
trieval was performed by microwave boil-
ing in T-EG buffer/TRS buffer (Dako).
Primary antibody detection was either
horseradish peroxidase (HRP)- conjugated
EnVision™ polymer (K4001; Dako), 
PowerVision Poly-HRP (Novocastra;
Leica Microsystems) or EnVison FLEX
(K8010; Dako) with 3,3′-diaminobenzidine
(DAB) (K3468; Dako) as chromogen. 
Microscopy of tissues was performed on a
Leica DMLB microscope (100×/nummeri-
cal aperture [NA] 1.25; Leica Microsys-
tems) using LasV3.6 acquisition software.
Animals and Surgery
Orthotopic transplantation of tumor
cells was achieved by injection into sur-
gically exposed mammary fat pads of
anesthetized NOG or CB-17 severe com-
bined immunodeficienc (SCID) female
mice aged 8 wks (Taconic, Ejby, Den-
mark). Before inoculation, cells were re-
suspended in extracellular matrix from
the Engelbreth-Holm-Swarm sarcoma
(Sigma-Aldrich) and culture medium.
Endpoint was a tumor size of 1.2 cm or
tumor growth for 6 months. The mice
were euthanized by cervical dislocation,
and tumors were fixed in formalin and
paraffin embedded. For evaluation of
metastatic potential of A4 and G4 cells,
106 Luc2-transfected cells were injected
into the tail veins of NOG mice. Relative
quantification of metastasis was per-
formed every second week for 8 wks by
using whole-body bioluminescent imag-
ing (IVIS spectrum; Caliper Life Sciences,
Hopkinton, MA, USA). Mice were in-
jected with 150 mg D-luciferin/kg body
weight, gas anesthetized with isoflurane
and imaged. Data analysis was per-
formed using Caliper Life Sciences Liv-
ing Image (version 4.0). All animal proce-
dures were performed in accordance
with a protocol approved by the Experi-
mental Animal Committee, The Danish
Ministry of Justice.
Proliferation Inhibition Assay
Twenty-four hours after seeding, cells
were subjected to chemotherapeutics
(two-fold dilutions of the drug from a
concentration wherein the most sensitive
of the cell lines had a 70–90% reduction
in relative proliferation) (0.2–40 μmol/L
paclitaxel, 0.05–0.8 μmol/L doxoru-
bicin, 0.07–75 μmol/L methotrexate,
0.13–20 μmol/L salinomycin) for 96 h,
followed by replacement of MEBM 
without phenol-red (Gibco; Life Tech-
nologies Corporation) containing 10% 
5 mg/mL MTT solution (Sigma-Aldrich).
After 4 h of incubation, 100 μL MTT sol-
vent was added to dissolve the insoluble
formazan crystals. The amount of for-
mazan was colorimetrically measured at
590 nmol/L. P values are based on two-
sided t tests of  triplicates.
Quantitative Proteomics
HMT3909S13 was subjected to “stable
isotope labeling by amino acid in cell
culture” (SILAC) to allow quantitative
comparison of proteins/peptides by
mass spectrometry (35,36). HMT3909S13
was propagated as described above,
but in custom-made MEBM without
L-arginine, L-lysine and L-glutamine
(Lonza) supplemented with L-glutamine
and either light (12C6) or heavy (
13C6) ly-
sine and arginine (12C6 [Sigma-Aldrich];
13C6 [Cambridge Isotope Laboratories,
Andover, MA, USA]). Cells (12C6 and
13C6) were mixed 1:1 and labeled with
antibodies for flow cytometry sorting
into CD44hi/CD24– and CD44hi/CD24lo.
Sorted cells were lysed in a hypotonic
buffer (10 mmol/L Tris-base, 1.5 mmol/L
MgCl2, 10 mmol/L NaCl, pH 6.8) supple-
mented with protease inhibitors (Roche)
followed by sedimentation (300g, 5 min),
resuspension in a  gradient buffer
(0.25 mol/L sucrose, 10 mmol/L HEPES,
100 mmol/L succinic acid, 1 mmol/L
EDTA, 2 mmol/L CaCl2, 2 mmol/L
MgCl2, pH 7.4), and homogenization
using a motor-driven Potter homoge-
nizer (Sartorius; Fisher Scientific GmbH,
Schwerte, Germany). After enzymatic di-
gestion with lysyl endoproteinase and
trypsin, peptides were analyzed by liq-
uid  chromatography–tandem mass spec-
trometry (LC-MS/MS; Q-TOF Micro Tan-
dem Mass Spectrometer; Waters
Corporation, Milford, MA, USA) using a
2-h stepped linear gradient (37). All rele-
vant mass spectrometry spectra were val-
idated manually to ensure high signal-to-
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noise ratios. Only proteins that exhibited
altered expression in at least two sam-
ples and were identified with at least
two peptides were subjected to further
analysis.
Real-Time Polymerase Chain Reaction
Relative quantification of gene expres-
sion was performed in triplicate using
SYBR Green PCR Master Mix (Applied
Biosystems; Life Technologies Corpora-
tion). Median relative expression levels
were normalized by using the reference
genes TATA box binding protein (TPB), 
β-actin and Na+/K+ ATPase (ATP1A1).
The primers for specific amplification
were obtained from QuantiTect Primer
assays collection (Qiagen, Hilden, Ger-
many): TBP: QT00000721; β-actin:
QT00095431; ATP1A1: QT00059962; VIM:
QT00095795; MUC1: QT00015379;
KRT6A: QT01666791; KRT19: QT00081137;
S100A14: QT00217028. Primers for CD24
were obtained from Invitrogen: F (CD24)
GCACT GCTCC TACCC ACGCA
GATTT, R (CD24) GCCTT GGTGG
TGGCA TTAGT TGGAT; and primers for
CD44 were obtained from Hill et al. (38):
F (CD44) TTTGC ATTGC AGTCA
ACAGT C, R (CD44) GTTAC ACCCC
AATCT TCATG TCCAC.
Quantitative Transcriptomics
mRNA was purified by TRIzol fol-
lowed by ethanol precipitation. Each cell
line in five biological replicates was ana-
lyzed on GeneChip® Human Gene 1.0 ST
Arrays (Affymetrix, Santa Clara, CA,
USA). Microarray data were normalized
and processed using the Partek® Ge-
nomics Suite (false discovery rate [FDR]
0.01) (Gene Expression Omnibus [GEO]
accession number GSE32455). Out of 599
genes, 406 were compared with a pub-
licly available data set (GEO accession
number GSE7390) (39) as training set for
a prognostics signature. The training set
was divided into ER+ (n = 134) and ER–
(n = 64) patients before classification. The
remaining 193 genes were not used be-
cause of absence of probe IDs or tran-
scripts in the patient data. Data from
GSE2990 (40) (KJ125) was chosen as the
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Figure 1. Phenotypic characterization of single-cell clones obtained from the parental cell
line, HMT3909S13, demonstrates G4 as CD44hi/CD24– with a mesenchymal-like morphology
and A4 as CD44hi/CD24lo with an epithelial-like morphology capable of forming mam-
mospheres. A4 cells can recapitulate cells similar to the parental cell line in vivo. (A) CD44
and CD24 expression of HMT3909S13 as determined by flow cytometry. The CD44hi/CD24–
G4 and CD44hi/CD24lo A4 single-cell clones were obtained from marked gates. G4 ex-
hibits a mesenchymal-like morphology, whereas A4 exhibits an epithelial-like morphology,
as determined by phase contrast imaging. (B) Relative CD24 expression of HMT3909S13,
A4 and G4 compared with the MDA-MB-231, T47D and MCF7 cell lines, as determined by
flow cytometry. HMT3909S13 without primary antibody is shown as a representative nega-
tive control. (C) Mammospheres were formed from A4, but not G4, after growth of cells in
nonadherent culture flasks at d 7, as depicted by phase contrast imaging. Only loosely
adhered clumps of cells were observed in the G4 cell culture flask. Scale bar: 30 μm. (D)
ICC analysis of CD24, vimentin, ESA and E-cadherin demonstrating altered expression lev-
els between the three cell lines. Scale bar: 20 μm. (E) IHC staining of primary tumors from
immunodeficient mice generated by inoculation of A4 and HMT3909S13 cells, respec-
tively, into the mammary fat pad showing the ability to express the proteins heteroge-
neously and more similar to the A4 than HMT3909S13 cells in vitro, emphasizing the CSC-
like characteristics of A4 clone cells. See also Supplementary Figures S2 and S3 and
Supplementary Table S1.
testing set (n = 34). Only data sets were
chosen with available information on pa-
tient ER+/ER– status, time to distant
metastasis, negative lymph node status
and no systemic treatment in addition to
data sets obtained from Affymetrix plat-
forms. Kaplan-Meier plot and Cox pro-
portional hazard regression model was
performed on the two data sets (n = 98)
using Partek Genomics Suite (Partek Inc.,
St. Louis, MO, USA).
Western Blotting
On the basis of protein concentration,
equal amounts of cell lysates were re-
solved on 4–20% sodium dodecyl
 sulfate–polyacrylamide gel electrophore-
sis (SDS-PAGE) (Pierce; Thermo Fisher
Scientific, Rockford, IL, USA) and elec-
troblotted onto a polyvinylidene fluoride
(PVDF) membrane. The membranes were
blocked and incubated with primary an-
tibody and HRP-conjugated secondary
antibody, respectively. The immunoreac-
tive bands were visualized using an ECL
Western Blot Kit (GE Healthcare, Buck-
inghamshire, UK). Loading of equal
amounts of lysate in each lane was fur-
ther validated by Coomassie staining of
the PVDF membrane.




Single-Cell Clones with CSC-Like
Features
To study the CD44hi/CD24–/lo sub-
population at a single-cell level, a panel
of breast cancer cell lines was examined
for CD44/CD24 expression to identify
one that contained a high percentage of
CD44hi/CD24–/lo cells. The triple-
 negative cell line HMT3909S13, which is
also known to exhibit a bilineage phe-
notype, was found to fulfill this require-
ment, and a large panel of isogenic cell
clones with different phenotypes was
isolated by flow cytometry sorting of
HMT3909S13 by using the gates
CD44hi/ CD24– and CD44hi/CD24lo, re-
spectively, and transfer of the sorted
cells directly into individual wells for
single-cell cloning. Two single-cell
clones were selected for further compar-
ison and designated CD44hi/CD24–
(clone G4) and CD44hi/CD24lo (clone
A4), respectively (Figure 1A). The level
of CD24 expression in G4 was equal to
that of the basal B-cell line, MDA-MB-
231, which is characterized as CD24–.
The level of CD24 expression in A4 was
10- and 20-fold lower, respectively, com-
pared with the luminal cell lines T47D
and MCF7, usually designated CD24+
(Figure 1B) (8,41). The level of CD24 ex-
pression differed six-fold between the
CD44hi/CD24– G4 clone and the
CD44hi/CD24lo A4 clone. The CD44hi/
CD24– G4 cells exhibited a spindle shape
consistent with a mesenchymal-like
morphology resembling basal B cells,
whereas the CD44hi/CD24lo A4 cells
were shaped like cobblestones and grew
in clusters, consistent with an epithelial-
like morphology resembling basal A
cells (see Figure 1A). G-band karyotyp-
ing of the HMT3909S13, G4 and A4
showed identical genetic abnormalities
in all three cell lines, confirming the iso-
genic background (Supplementary Fig-
ure S1). A total of 44 additional single-
cell clones obtained from HMT3909S13
were analyzed according to CD44/CD24
phenotypes and morphology. The ma-
jority of the CD44hi/CD24– phenotype
clones exhibited mesenchymal-like
morphology, whereas the majority of
clones with a CD44hi/CD24lo  phenotype
exhibited  epithelial-like morphology.
Some clones also exhibited a reverse 
relationship or mixed populations, 
indicating that CD24 levels in the
CD44hi/ CD24–/lo subpopulation are not
directly associated with individual cell
morphology (42).
The ability to self-renew and form
mammospheres in vitro was examined by
seeding single-cell suspensions in nonad-
herent culture flasks, resulting in mam-
mosphere formation of CD44hi/CD24lo
A4 clone within 2 wks. These could, by
dissociation and upon transfer to new
flasks, lead to new mammospheres. In
contrast, the CD44hi/CD24– G4 clone
mostly produced loosely adherent
clumps of cells (Figure 1C).
The two clones and the parental
HMT3909S13 cell line were next stained
with a panel of antibodies against rele-
vant markers (Figure 1D, Supplementary
Table S1). The expression of ER, PR and
HER2 were negative in all three cell
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Figure 2. Only the CD44hi/CD24lo A4 and
the parental HMT3909S13 cell lines initiated
tumors in immunodeficient mice. (A) Tumor
formation upon orthotopic inoculation into
the mammary fat pad of CD44hi/CD24–
G4, CD44hi/CD24lo A4, HMT3909S13 or
Hs578T cells into two strains of immunodefi-
cient mice (CB17-SCID and NOG). Ratios
refer to the number of mice in which pri-
mary tumors developed relative to total
number of mice inoculated with cells
within each group. (B) Tumors established
after orthotopic inoculation of 104 A4 cells
in a NOG mouse (right, arrow), whereas no
tumor formation was observed in any of
the NOG mice orthotopically inoculated
by 106 G4 cells (left). (C) Whole-body biolu-
minescent imaging of lung metastases es-
tablished after tail vein inoculation of 106
Luc2-transfected A4 or G4 cells.
lines, whereas the relatively absent and
low expression level of CD24 in G4 and
A4, respectively, as observed by flow cy-
tometry, were validated by ICC. Vi-
mentin, cytokeratin 17 and E-cadherin
exhibited higher expression and cytoker-
atins 5/6 lower expression in G4 versus
A4 cells. However, E-cadherin was ex-
pressed in a larger percentage of A4 com-
pared with G4 cells. More A4 than G4
cells expressed ESA, but with approxi-
mately equal intensities. Cytokeratins
7/8, 14, 18 and 19; HER1; and integrins
β1 and α6 were equally expressed in the
two cell lines. Interestingly, HMT3909S13
did not express E-cadherin or ESA,
whereas both the G4 and A4 cells
showed intense expression, although at
varying levels, supporting the CSC fea-
tures of the selected clones.
The cell lines are considered stable since
the A4 and G4 clones have been grown
discontinuously under stable growth con-
ditions and in the presence of growth fac-
tors for >2 years without phenotypic
changes (Supplementary  Figure S2).
An Epithelial-Like CSC-Like Clone, but
Not a Mesenchymal-Like CSC-Like
Clone, Exhibited In Vivo Tumor
Initiation Capacity
CD44hi/CD24– G4, CD44hi/CD24lo A4
and HMT3909S13 were inoculated into
the mammary fat pad of two strains of
immunodeficient mice, CB17 SCID and
NOG. Primary tumors were formed
within a period of 90 d upon orthotopic
inoculation of as low as 103 A4 cells and
105 HMT3909S13 cells, respectively,
whereas no tumor formation was ob-
served from inoculation of up to 106 G4
cells after 180 d of observation (Fig-
ures 2A, B). The percentage of mice that
formed tumors upon inoculation with A4
cells was higher in NOG mice than in
CB17-SCID mice. Metastatic potential was
evaluated by tail vein injection and
whole-body bioluminescent imaging of
Luc2 transfected A4 and G4 cell lines in
NOG mice and revealed that lung metas-
tases were established within a period
of 3 wks by injection of 106 A4 cells. How-
ever, G4 did not give rise to lung metas-
tases within a period of 8 wks (Figure 2C).
Whereas well-characterized basal A
cell lines (for example, BT20 and MDA-
MB-468) are known to establish tumors
in immunodeficient mice (43), the lack of
tumor potential of basal B cells, other
than G4, was examined by inoculation of
106 cells of another well-characterized
basal B-cell line, Hs578T (32), into the
mammary fat pad of NOG mice. The cell
line did not show any sign of tumor for-
mation after 90 d of observation.
IHC staining was performed to evalu-
ate whether the tumor cells in the pri-
mary tumors established by A4 and
HMT3909S13 cells exhibited the same
markers as the cells used for inoculation
(Figure 1E). Comparing the expression
of CD24, vimentin, ESA and E-cadherin
in the primary tumors established by A4
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Figure 3. CD44hi/CD24lo A4 cells are significantly more resistant to conventional
chemotherapeutic reagents, but are more sensitive to salinomycin treatment than
CD44hi/CD24– G4 cells. (A) Relative reduction in proliferation of A4 and G4 cells after
treatment with various chemotherapeutics in at least four different concentrations for
96 h, as determined by an MTT proliferation assay. Three independent experiments were
performed, and a representative experiment is shown. *p < 0.01. (B) Phase contrast pic-
tures of G4 versus A4 treated for 10 d with 0.4 or 1 μmol/L doxorubicin, respectively. The ar-
rows show dead Tryphan blue–stained cells. (C) CD24 expression of HMT3909S13 as shown
by flow cytometry after treatment with 0.4 μmol/L doxorubicin, 40 μmol/L methotrexate, 
5 μmol/L paclitaxel or 2 μmol/L salinomycin for 10 d, showing a selection of doxorubicin-,
methotrexate- and paclitaxel-treated cells that express more CD24 compared with un-
treated cells. No selection is observed with salinomycin treatment.
with that of A4 cells in vitro showed
some differences, for example, vimentin
and E-cadherin were more highly ex-
pressed in the primary tumor established
by A4 compared with A4 cells grown in
vitro, and ESA became more heteroge-
neously expressed in the primary tumor.
Interestingly, the staining pattern of the
tumors formed by inoculation of A4 and
HMT3909S13 cells, respectively, closely
resembled each other. This result indi-
cates that inoculation of A4 cells into
mice leads to primary tumors containing
cells with diverse expression patterns of
epithelial/ mesenchymal markers that re-
capitulate the original heterogeneity of
HMT3909S13 cells.
An Epithelial-Like CSC-Like Clone
Exhibited More Resistance to
Conventional Chemotherapy than a
Mesenchymal-Like CSC-Like Clone
To evaluate the sensitivity/resistance
of G4 and A4 to different chemothera-
peutic compounds, the cells were treated
for 96 h in vitro with the conventional
chemotherapeutics doxorubicin (antra-
cycline, 0.05–0.8 μmol/L), paclitaxel
(taxane, 0.2–40 μmol/L) and methotrex-
ate (antifolate, 0.07–75 μmol/L), as well
as salinomycin (antibacterial ionophore,
0.125–20 μmol/L), which recently were
reported to predominantly target CSCs
(44). Sensitivity/resistance toward
chemotherapeutic compounds was mea-
sured using an MTT proliferation assay
that showed the relative reduction in
proliferation after chemotherapy treat-
ment in vitro (Figure 3A), whereas the
death of treated cells was shown by
Tryphan blue staining and cell counting
(Figure 3B). The A4 clone was signifi-
cantly (p < 0.01) more resistant to dox-
orubicin, methotrexate and paclitaxel
treatment than G4. In contrast, G4 was
significantly (p < 0.01) more resistant to
salinomycin treatment than A4.
HMT3909S13 cells that survived treat-
ment with conventional chemotherapeu-
tics were stained for CD44 and CD24 and
compared with untreated cells by flow
 cytometry. Interestingly, treatment with
0.4 μmol/L doxorubicin, 40 μmol/L
methotrexate or 5 μmol/L paclitaxel for
10 d led to an eight-, three- and two-fold
higher mean fluorescence intensity for
CD24, respectively, compared with un-
treated cells. On the basis of the expres-
sion of CD24, treatment with salino-
mycin (2 μmol/L) did not select for a
specific population (Figure 3C). CD44 ex-
pression showed no changes after any of
the above treatments compared with the
untreated cell line. This result suggests
that only cells expressing some CD24
(such as the A4 cells) survived treatment
with doxorubicin, methotrexate and
 paclitaxel.
Novel Markers Distinguishing the
CD44hi/CD24–/lo Subsets Identified by
Quantitative Proteomics
Proteins distinguishing the CD44hi/
CD24lo and CD44hi/CD24– phenotypes
were identified by comparative quantita-
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Figure 4. Identification of proteins exhibiting altered expression levels between CD44hi/
CD24lo and CD44hi/CD24– cells using comparative quantitative mass spectrometry–based
proteomics of SILAC cells and validation of selected proteins. (A) A list of proteins exhibit-
ing altered expression between CD44hi/CD24lo and CD44hi/CD24– cells. (B) ICC with esti-
mated staining intensity and number of cells expressing CK6A, MUC1 and S100A14 in G4,
A4 and the parental cell line compared with IHC of primary tumors established with A4
and HMT3909S13 inoculated into NOG mice. Scale bar: 20 μm. (C) Fold-change expres-
sion levels of mRNA of selected candidates in A4 and G4 measured by quantitative real-
time PCR identifying CD24, MUC1, KRT6A (CK6A), KRT19 (CK19 ) and S100A14 upregulation
in A4 at the mRNA level, whereas VIM is downregulated compared with G4. The number 1
(y axis) corresponds to equal mRNA expression in the two cell lines.
tive mass spectrometry of SILAC-labeled
cells sorted from the parental cell line
HMT3909S13 (Figure 4A). A number of
cytokeratins (CK5, CK7, CK8, CK18 and
CK19) and vimentin, in the proteomic
study, exhibited altered expression be-
tween CD44hi/CD24lo versus CD44hi/
CD24–. In addition, four potentially in-
teresting proteins (S100A14, MUC1,
CK6A and ribosomal protein L7) exhib-
ited  altered expression. Three of these
(S100A14, MUC1 and CK6A) were vali-
dated by ICC, showing more intense
CK6A and S100A14 staining in A4 ver-
sus G4 cells, whereas more A4 than G4
cells stained for MUC1. Fewer cells in
the HMT3909S13 cell line than in the A4
and G4 sublines expressed S100A14,
MUC1 and CK6A. IHC of primary tu-
mors generated from A4 and
HMT3909S13 cells for MUC1 and
S100A14 showed staining similar to ICC
of A4, whereas CK6A showed a more
heterogeneous staining, similar to G4
cells (Figure 4B). The observed altered
protein expression levels of all three pro-
teins (MUC1, S100A14 and CK6A) were
shown to correspond with alterations in
mRNA expression  levels measured by
quantitative real-time polymerase chain
reaction (PCR) (Figure 4C).
Gene Array Profiling of the
CD44hi/CD24–/lo Subsets Revealed
Novel Markers and Pathways Linked
to Tumor-Initiating Cells as well as a
Prognostic Gene Signature
To define a gene expression signature
of CSC-like cells with tumor-initiating
and chemoresistant potential, gene ar-
rays of five biological replicates of
CD44hi/CD24lo A4 and CD44hi/CD24–
G4, respectively, were compared, reveal-
ing 1,777 genes that were upregulated
and 1,883 that were downregulated (p <
0.0001, FDR 0.01). Of these, 599 genes ex-
hibited more than two-fold difference in
A4 versus G4 (Figure 5A and Supple-
mentary Table S2). The fold-changes
were in the range of 2- to 71.7-fold. Inge-
nuity pathway analysis revealed several
networks, including a network of 59
genes that were upregulated more than
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Figure 5. Transcriptomic analysis of CD44hi/CD24lo G4 and CD44hi/CD24– A4 clones identi-
fying genes and gene signatures related to the CSC-like phenotype and potential new
biomarkers. (A) Heat map of the genes differentially expressed more than two-fold in A4
relative to G4 (FDR 0.01), showing representative gene clusters. (B) Heat map focusing on
gene expression levels of EMT markers: VIM, transcription factors (ZEB1, ZEB2, TWIST1), snail 1
and 2 (SNAI1/SNAI2), matrix metalloproteinase-2 (MMP2), E-cadherin (CDH1) and
claudins (CLDN3, CLDN4, CLDN7) and CSC markers: CD24, CD44, aldehyde dehydroge-
nase (ALDH1A1), epithelial cell adhesion (ESA) molecule, MUC1, integrin β1 (ITGB1) and in-
tegrin α6 (ITGA6). Each colored square represents the relative transcript abundance (log
2 space) of each of five biological replicates of A4 and G4, respectively. Highest expres-
sion is red and lowest is blue. (C) Flow cytometry analysis of LSR and RAB25 showing
higher expression in A4 versus G4. Controls without primary antibody were included. (D)
Comparison of the expression levels of ZEB1 and LSR in G4, A4 and HMT3909S13 by ICC
showing higher expression of ZEB1 and lower expression of LSR in G4 versus A4. Scale bar:
20 μm. (E) Western blotting of ZEB1 and S100A14 showing higher expression of ZEB1 and
lower expression of S100A14 in G4 versus A4. The parental cell line (HMT3909S13) shows in-
termediate expression of both proteins. See also Supplementary Figure S4 and Supple-
mentary Table S2.
three-fold in A4 versus G4, including
CDH1, MUC1, JUP, DSP, MUC16 and
FOXA1, genes already known to be in-
volved in cancer, reproductive systems
and genetic disease (Supplementary Fig-
ure S4).
Focusing on important pathways de-
scribed for EMT and CSC, the expression
of central genes were evaluated. Expres-
sion of epithelial cell–cell adhesion genes,
such as E-cadherin, claudin 3, claudin 4,
claudin 7 and occludin, were significantly
higher in A4 than G4, whereas EMT
markers such as vimentin, twist1, matrix
metalloproteinase 2, ZEB1 and ZEB2
were lower in A4 versus G4. Snail1 and
snail2 were fairly equally expressed be-
tween the two clones. Protein markers of
CSC and epithelial differentiation, such
as MUC1, ESA, CD24 and aldehyde de-
hydrogenase, were more highly ex-
pressed in A4 versus G4, whereas CD44,
integrin α6 and integrin β1 were more
highly expressed in G4 versus A4 (Fig -
ure 5B). To identify potential novel bio-
markers capable of distinguishing
CD44hi/ CD24–/lo cancer cells with and
without tumorigenic and chemoresistant
potential in a tumor cell population of
triple-negative breast cancer, candidate
biomarkers were selected from genes that
exhibited extensive alteration in expres-
sion between A4 versus G4. These genes
were examined at the protein level, in-
cluding LSR, RAB25 and S100A14, which
were upregulated at the mRNA levels 11-,
24- and 10-fold, respectively, in A4 versus
G4 and ZEB1, which was upregulated 11-
fold in G4. The higher expression of the
cell surface proteins LSR and RAB25 in
A4 versus G4 were confirmed by flow cy-
tometry (Figure 5C). LSR and ZEB1 were
examined by ICC, showing higher ex-
pression of LSR and lower expression of
ZEB1 in A4 versus G4, respectively (Fig-
ure 5D). The altered expression of ZEB1
was also confirmed by Western blotting
(Figure 5E). Additionally, Western blot-
ting demonstrated higher expression of
S100A14 in A4 versus G4 (see  Figure 5E).
To examine whether A4 and G4 exhib-
ited characteristics similar to the basal A
and basal B subpopulations, the expres-
sion of selected proteins that exhibited
altered expression in A4 versus G4 was
analyzed in well-characterized cell lines
of basal A (MDA-MB-468 and BT20) and
basal B (Hs578T) by using ICC. Similar
to A4, MDA-MB-468 and BT20 exhibited
higher expression of S100A14, LSR,
MUC1 and ESA than G4 and Hs578T.
Similarly, G4 and Hs578T exhibited
higher expression of vimentin and ZEB1
compared with A4, MDA-MB-468 and
BT20 (Figures 1D, 4B, 5D and 6).
As it may be expected that breast can-
cers exhibiting a higher frequency of
CSC may have a poor outcome and more
frequent disease recurrence, we exam-
ined whether some of the 599 genes
identified by comparison of A4 and G4
could predict distant metastasis of lymph
node–negative primary breast cancers. A
microarray data set of 198 tumor samples
of lymph node–negative breast cancer
patients who had received no adjuvant
systemic treatment was divided into ER+
and ER– patients (39). Because our cell
model system was generated from an
ER– tumor, it was expected that the gene
signature only would relate to this breast
cancer subtype. The study contained 64
ER– patients, of which 25 developed dis-
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Figure 6. Proteins identified to exhibit altered expression between A4 and G4 were further
analyzed in cell lines of basal A and basal B subtype. (A) ICC of S100A14, LSR, MUC1 and
ESA showed higher expression in the basal A cell lines, BT20 and MDA-MB-468, relative to
the basal B cell line, Hs578T. (B) Vimentin and ZEB1 showed higher expression in the basal
B cell line relative to the basal A cell lines.
tant metastasis within a 5-year period
(Figure 7A). A 31-gene signature was
identified in this training set by using a
leave-one-out cross-validation procedure
with the K-nearest neighbor algorithm as
a classifier (Figure 7B). Subsequently, the
accuracy of the 31-gene signature was
tested in an independent set of 34 pa-
tients (40) combined with the training
set, demonstrating an accuracy of 86.6%
(sensitivity of 70.37%, specificity of 97%).
The very high specificity indicates that
the signature is accurate in identifying
patients with triple-negative breast can-
cer who will not experience recurrence.
Interestingly, when similar analysis was
performed on the ER+ subgroup of the
microarray training data set, no signa-
ture with high prognostic accuracy
could be identified. A Kaplan-Meier plot
illustrates survival analysis of untreated,
ER– and node-negative breast cancer co-
horts classified as metastatic or non-
metastatic by the 31-gene signature.
Metastatic patients had significantly
shorter relapse-free survival time (p <
0.00001; metastatic versus nonmetastatic
mean/median: 938 versus 3,493 d/440
versus 3,688 d) and distant metastasis-
free survival (p < 0.00001; metastatic 
versus nonmetastatic mean/median:
1,630 versus 3,640/743 versus 4,124 d)
compared with those classified by the
signature as nonmetastatic (Figure 7C).
Relapse-free survival was defined as the
interval between the date of breast sur-
gery and the date of diagnosis of any
local, regional or distant relapse. Fur-
thermore, multivariate Cox regression
analysis using clinical parameters in-
cluding age, tumor size, tumor grade
and 31-gene signature class (metastatic/
nonmetastatic) revealed that only the
signature class significantly correlated
with distant metastasis-free survival
(hazard regression 0.19; p < 0.00001).
The 31-gene signature includes some
of the genes/proteins we had already
biochemically validated, such as LSR and
ESA. These markers were originally se-
lected from the 599-gene expression list
on the basis of reports in the literature
indicating their potential role in cancer
progression.
DISCUSSION
The CSC theory of tumorigenesis may
have major implications for clinical treat-
ment practice. This potential may be par-
ticularly significant for triple-negative or
basal-like breast cancers, the focus of this
study, since chemotherapy is the only
medical treatment for this subtype; the
known targeted treatments, such as en-
docrine and anti-HER2 therapy, have no
effect in this patient group. Considering
that CSCs are generally more resistant to
standard chemotherapy, it is not surpris-
ing that chemotherapy is of limited use,
and this subgroup has a poor outcome.
Evidence of the presence of CSCs in
primary tumors has mainly relied on pri-
mary and early passage xenograft mod-
els (25,45), whereas a limited number of
cell lines, some generated by transform-
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Figure 7. A 31-gene breast cancer signature capable of predicting distant metastasis of
lymph node–negative ER– primary breast cancer. (A) A microarray data set of a total of
198 lymph node–negative breast cancer patients (64 ER– and 134 ER+) were used as a
training set to identify a 31-gene signature from the 599 genes exhibiting altered expres-
sion between A4 and G4. A testing set of 34 patients in combination with the training set
was used to validate the signature (39,40). (B) The 31 genes included in the prognostic sig-
nature of ER– patients. (C) Kaplan-Meier plots illustrating the probability of relapse-free and
distant metastasis-free survival predicted by the 31-gene signature. Upper curve (solid line)
illustrates patients predicted as metastasis-free within a 5-year (1,825-d) period. Lower
curve (dashed line) predicts patients with distant metastasis before a 5-year period.
ing normal mammary cells with onco-
genes, have been used to study stem cell
characteristics relative to functional and
phenotypic differences and to isolate
subpopulations with CSC characteristics
based on markers such as CD44hi and
CD24–/lo, ALDH1 and ESA (1,8,46). Ex-
amination at the single-cell level to iden-
tify novel markers and functionally char-
acterize CSCs is advantageous, although
technically difficult.
In this study, we isolated such single-
cell clones from an established cell line
and performed detailed characterization.
We found that the CD44hi/CD24lo A4
cells resembling cells of the previously
described basal A cluster (32), which
closely matches the Perou basal–like sig-
nature (31,32,47,48), could form mam-
mospheres, which could be propagated.
These cells could also initiate tumors in
mice when as few as 1,000 cells were im-
planted into the mammary fat pad, and
these tumors recapitulated the pheno-
type of the parental cell line. A4 cells
showed metastatic potential in the lungs
and also exhibited resistance to standard
chemotherapeutic drugs, all hallmarks of
breast CSCs. Surprisingly, whereas ear-
lier models for breast CSCs have shown
that these cells exhibit a mesenchymal-
like phenotype (31), the A4 cells exhib-
ited a clear epithelial-like phenotype
both with regard to morphology and
 molecular markers. In contrast, the
CD44hi/CD24– G4 clone, which exhibited
a mesenchymal-like phenotype and re-
sembles the previously described basal
B cells, could not form mammospheres,
tumors or metastasis, even when 106 cells
were implanted, and were less resistant
to traditional chemotherapeutic drugs.
However, it should be mentioned that at
least one cell line with basal B character-
istics, MDA-MB-231 (32,43), was shown
to be tumorigenic in immunodeficient
mice (49,50); however, MDA-MB-231
cells are derived from a pleural effusion,
whereas HMT3909S13 is derived from a
primary tumor, which may contribute to
the different tumorigenic behavior. It is
of interest that primary tumors estab-
lished by A4, in contrast to A4 cells in
culture, expressed the mesenchymal
marker vimentin, indicating that EMT
had occurred during the process of es-
tablishing the tumor. We presume that
not all tumor-initiating cells in this
model exhibit an epithelial-like pheno-
type, as suggested by the heterogeneity
of the epithelial-like/mesenchymal-like
morphology and CD44/CD24 expression
of the CD44hi/CD24lo single-cell clones
isolated from HMT3909S13, but it dem-
onstrates that it is not a prerequisite for
breast CSC to exhibit a mesenchymal-like
morphology. The transition of cells ob-
served in vivo also supports the observa-
tions made by Gupta et al. (16), who
showed that cells are in transition be-
tween states to obtain phenotypic equi-
librium in populations of cancer cells.
Further, a recent study by Kim et al. (51)
demonstrated that, within a single
tumor, there are multiple stemlike cells
with tumorigenic potential.
ALDH1 and ESA have been suggested
as additional CSC markers in breast can-
cer (1,9,46,52,53). Interestingly, our tran-
scriptomic analysis revealed higher ex-
pression of ALDH1 and ESA in A4
versus G4. Further, our quantitative pro-
teomic and transcriptomic analysis re-
vealed a panel of additional markers that
are more highly expressed in A4 versus
G4, such as MUC1, S100A14 and LSR,
proteins that have potential as novel
markers and/or targets of CSC subpopu-
lations. These markers were also more
highly expressed in basal A cell lines
(BT20 and MDA-MB-468) than basal
B cell lines (Hs578T), as shown by ICC.
Markers such as vimentin and ZEB1
showed higher expression in G4 and
basal B cell lines compared with A4 and
basal A cell lines, verifying that the data
obtained by our bilineage model could
be confirmed in other model systems.
The basal A cell lines, such as A4, are tu-
morigenic in athymic nude mice (43),
whereas the basal B cell lines and G4 are
nontumorigenic in NOG mice.
Despite the lack of ESA, E-cadherin
and CD24 expression in the HMT3909S13
cell line in vitro, high expression of all
three proteins were obtained in vivo after
inoculation, indicating a small CSC-like
population within HMT3909S13 harbor-
ing features similar to A4.
On the basis of the genes that exhibit
altered expression between A4 and G4,
we identified a 31-gene prognostic signa-
ture able to predict distant metastases in
triple-negative and lymph node–negative
breast cancer patients. The accuracy of
this profile was confirmed in a second
cohort of triple-negative breast cancer
patients, but was found not to be the
case in ER+ breast cancer patients, indi-
cating that CSCs differ between breast
cancer subtypes. Thus, the prognostic
profiles should be subtype specific. The
specificity of 97% is substantially higher
than generally reported (54,55) and dem-
onstrates that this signature is a highly
accurate indication of those patients with
triple-negative breast cancer who will
not experience recurrence. This assay
may, when further developed, be clini-
cally useful in avoiding the deleterious
side effects of overtreatment. Some of the
genes included in the signature, such as
ESA and LSR, also show promise as pro-
tein biomarkers of cells with CSC fea-
tures, either alone or in combination, and
may be used as future targeting of this
subpopulation of cells involved in tu-
morigenesis and chemoresistance. As ex-
pected for a CSC, A4 was more resistant
to doxorubicin, paclitaxel and methotrex-
ate relative to G4. In agreement with ear-
lier studies, A4 was less resistant to sali-
nomycin, a polyether antibiotic that acts
in different biological membranes as an
ionophore and that was recently shown
to selectively deplete breast CSCs from
mammospheres and inhibit breast tumor
growth in mice by as yet unknown
mechanisms (44,56).
CONCLUSION
We propose that the A4 and G4
single-cell clones represent subgroups
within a CD44hi/CD24–/lo population in
which only epithelial-like A4 cells con-
tain the traditional described CSC prop-
erties. The clones give rise to a 31-gene
signature identifying ER– cancer pa-
tients who are not likely to develop dis-
R E S E A R C H  A R T I C L E
M O L  M E D  1 8 : 1 1 0 9 - 1 1 2 1 ,  2 0 1 2  |  L E T H - L A R S E N  E T  A L .  |  1 1 1 9
tant metastasis. The two cell types also
seem to represent the previously de-
scribed basal A and basal B subtypes.
The study challenges the current view
that breast CSCs only exhibit a mes-
enchymal-like phenotype, since we
demonstrate that cells with different
phenotypes have CSC-like properties.
The clones were propagated discontinu-
ously for more than 2 years without
changing characteristics. Thus, these
single-cell clones may represent a
unique model for CSC marker discov-
ery, some of which have been identified
here. In addition, the single-cell clones
may be useful for evaluation of the effi-
cacy of novel combinatorial drugs tar-
geting different cell types as well as for
elucidating the biology of CSCs.
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